-
Share
26/10/09
15:02
Share
I think there is another factor and thus higher royalities to Biota.
Firstly, if you use a figure of 300 million US population and a $US20 per course for relenza & 7% royality. You can run up these numbers
1. Old Pandemic Stockpile mix: 80% Tamiflu, 20% Relenza
Biota royality from this market alone is USD 13.4 million.
2. New Pandemic Stockplie mix: 50% Tamiflu, 50% Relenza
Biota royality from this market alone is USD 33.6 million
Secondary factor
If the stockpile plan follows WHO recommendation of 50% population coverage instead of 20% coverage
then the royalty number is USD 52.5 million
With the EU, Japan, Canada etc thrown in the mix, the numbers looks quite interesting
-